Perioperative management in patients receiving newer oral anticoagulant and antiaggregant agents [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2012; 40(6): 548-551 | DOI: 10.5543/tkda.2012.44977

Perioperative management in patients receiving newer oral anticoagulant and antiaggregant agents

Bilgehan Karadağ, Barış İkitimur, Zeki Öngen
Istanbul University, Cerrahpasa School of Medicine, Department of Cardiology, Istanbul, Turkey

It is anticipated that an increasing number of patients undergoing surgical procedures will be taking new anticoagulants and antiaggregants. Currently, only a small amount of data (which were derived from subgroup analyses of undedicated studies) exist regarding the optimal strategy in these patients. Clinical studies are urgently required to establish safe surgical procedures for this high risk patient population. Unlike warfarin, dabigatran and rivaroxaban have predictable and consistent anticoagulant effects with a rapid onset of action, short half-life, and consequently no need for routine laboratory testing. The pharmacologic profiles of these drugs represent an advantage for patients on chronic oral anticoagulant treatment who are undergoing invasive procedures. These drugs may minimize patient time spent without the antithrombotic effects of oral anticoagulants during the perioperative period, potentially eliminating the need for bridging therapy altogether.

Keywords: Anticoagulants/adverse effects, apixaban, dabigatran; drug administration schedule; drug interactions; hemorrhage/blood; perioperative care; prasugrel; risk factors; rivaroxaban; ticagrelor; administration, oral

How to cite this article
Bilgehan Karadağ, Barış İkitimur, Zeki Öngen. Perioperative management in patients receiving newer oral anticoagulant and antiaggregant agents. Turk Kardiyol Dern Ars. 2012; 40(6): 548-551

Corresponding Author: Barış İkitimur, Türkiye
© copyright 2018 Archives of the Turkish Society of Cardiology
LookUs & Online Makale